HomeAI · summaries
Storia in 4 fonti
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
ilpost.it
Un importante progresso nella ricerca sul tumore al pancreas
I test clinici di un nuovo farmaco hanno dato risultati incoraggianti su un modo di trattare la malattia considerato impossibile fino a qualche tempo fa
- ·
latercera.com
La debilidad de un cáncer letal y poco tratable que la ciencia logró encontrar - La Tercera
Daraxonrasib, una píldora experimental contra el cáncer de páncreas, mostró resultados prometedores en pacientes terminales al aumentar la supervivencia y mejorar la calidad de…
- ·
pbs.org
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
- ·
franceinfo.fr
"C'est une révolution" : pourquoi le daraxonrasib, un nouveau traitement contre le cancer du pancréas, suscite de grands espoirs
Cet anticancéreux multiplie par deux l'espérance de vie des patients atteints du cancer du pancréas, l'un des plus mortels et contre lequel peu de solutions existent. Les…